

nature biotechnology

EDITORIAL

837 Join the dots

NEWS

- 839 EGFR inhibitors embrace *KRAS*
- 840 GSK slashes internal R&D
- 841 Myriad stumbles, Wyeth closes on Alzheimer's
- 843 FDA and surrogate endpoints in Alzheimer's disease
- 844 Infections cast cloud over Novartis' MS therapy
- 845 India harmonizes regulations
- 845 FDA probes TNF blockers
- 846 GSK bird flu vaccine
- 846 Cabilly patent finale
- 846 UK strong arms industry over drug pricing
- 847 Pharma to boycott UK?
- 847 EC/FDA joint inspections
- 847 Supply size matters
- 849 PROFILE: Olivier Rabin
- 850 DATA PAGE: Q2 finance fall-off
- 851 NEWS FEATURE: Do biomaterials really mean business?

BIOENTREPRENEUR

BUILDING A BUSINESS

- 855 The economics of licensing contracts
Richard Mason, Nicos Sawva & Stefan Scholtes

OPINION AND COMMENT


CORRESPONDENCE

- 858 GMO testing—trade, labeling or safety first?
- 859 First evaluation of the European hESCreg
- 860 Guidelines for reporting the use of mass spectrometry in proteomics
- 862 Guidelines for reporting the use of mass spectrometry informatics in proteomics
- 863 Guidelines for reporting the use of gel electrophoresis in proteomics
- 864 The PSI-MOD community standard for representation of protein modification data

Nature Biotechnology (ISSN 1087-0156) is published monthly by Nature Publishing Group, a trading name of Nature America Inc. located at 75 Varick Street, F19, New York, NY 10013-1917. Periodicals postage paid at New York, NY and additional mailing post offices. **Editorial Office:** 75 Varick Street, F19, New York, NY 10013-1917. Tel: (212) 726 9335, Fax: (212) 696 9753. **Annual subscription rates:** USA/Canada: US\$250 (personal), US\$2,730 (institution), US\$4,050 (corporate institution). Canada add 7% GST #104911595RT001; Euro-zone: €202 (personal), €2,170 (institution), €3,488 (corporate institution); Rest of world (excluding China, Japan, Korea): £130 (personal), £1,400 (institution), £2,250 (corporate institution); Japan: Contact NPG Nature Asia-Pacific, Chiyoda Building, 2-37 Ichigayatamachi, Shinjuku-ku, Tokyo 162-0843. Tel: 81 (03) 3267 8751, Fax: 81 (03) 3267 8746. **POSTMASTER:** Send address changes to *Nature Biotechnology*, Subscriptions Department, 342 Broadway, PMB 301, New York, NY 10013-3910. **Authorization to photocopy** material for internal or personal use, or internal or personal use of specific clients, is granted by Nature Publishing Group to libraries and others registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided the relevant copyright fee is paid direct to CCC, 222 Rosewood Drive, Danvers, MA 01923, USA. Identification code for *Nature Biotechnology*: 1087-0156/04. **Back issues:** US\$45, Canada add 7% for GST. CPC PUB AGREEMENT #40032744. Printed by Publishers Press, Inc., Lebanon Junction, KY, USA. Copyright © 2008 Nature Publishing Group. Printed in USA.




An artist's impression of targeted delivery of cytotoxic drugs to a cancer cell by internalization of the complex formed between antibody-drug conjugate (ADC) and its antigen. Junutula *et al.* produce near-homogenous ADCs that are better tolerated than conventional ADCs without any loss of anti-tumor activity (p 925). Credit: Allison Bruce, Genentech, Inc.




First heat-conductive bioplastic, p 851




nature publishing group



Discovery of miRNA targets, p 881



Safer antibody-drug conjugates, p 884



Minimum-information guidelines, p 889

FEATURE

- 867 Off-label or off-limits?**
Mark Ratner & Trisha Gura

PATENTS

- 877 The London Agreement and the future of parallel imports**
Justine Muir
- 880 Recent patent applications in DNA synthesis**

NEWS AND VIEWS

- 881 Sequencing sliced ends reveals microRNA targets**
Ian R Henderson & Steven E Jacobsen **(b)** *see also p 941*
- 882 Nematology: terra incognita no more**
James P McCarter **(b)** *see also p 909*
- 884 Antibody-drug conjugates ace the tolerability test**
Nitin K Damle **(b)** *see also p 925*
- 886 A welcome burst of human antibodies**
Michael B Zwick, Johannes S Gach & Dennis R Burton
- 888 RESEARCH HIGHLIGHTS**

COMPUTATIONAL BIOLOGY

COMMENTARY

- 889 Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project**
Chris F Taylor, Dawn Field, Susanna-Assunta Sansone, Jan Aerts, Rolf Apweiler, Michael Ashburner, Catherine A Ball, Pierre-Alain Binz, Molly Bogue, Tim Booth, Alvis Brazma, Ryan R Brinkman, Adam Michael Clark, Eric W Deutsch, Oliver Fiehn, Jennifer Fostel, Peter Ghazal, Frank Gibson, Tanya Gray, Graeme Grimes, John M Hancock, Nigel W Hardy, Henning Hermjakob, Randall K Julian Jr, Matthew Kane, Carsten Kettner, Christopher Kinsinger, Eugene Kolker, Martin Kuiper, Nicolas Le Novère, Jim Leebens-Mack, Suzanna E Lewis, Phillip Lord, Ann-Marie Mallon, Nishanth Marthandan, Hiroshi Masuya, Ruth McNally, Alexander Mehrle, Norman Morrison, Sandra Orchard, John Quackenbush, James M Reecy, Donald G Robertson, Philippe Rocca-Serra, Henry Rodriguez, Heiko Rosenfelder, Javier Santoyo-Lopez, Richard H Scheuermann, Daniel Schober, Barry Smith, Jason Snape, Christian J Stoeckert Jr, Keith Tipton, Peter Sterk, Andreas Untergasser, Jo Vandesompele & Stefan Wiemann


PRIMER

- 897 What is the expectation maximization algorithm?**
Chuong B Do & Serafim Batzoglou


RESEARCH

PERSPECTIVE


- 901 Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment**
J Wang, J Lozier, G Johnson, S Kirshner, D Verthelyi, A Pariser, E Shores & A Rosenberg



Root-knot nematode genome, p 909



Chemical boost for RNAi, p 933



Enhanced reprogramming efficiency, p 941

ARTICLES

- 909 Genome sequence of the metazoan plant-parasitic nematode *Meloidogyne incognita***
P Abad, J Gouzy, J-M Aury, P Castagnone-Sereno, E G J Danchin, E Deleury, L Perfus-Barbeoch, V Anthouard, F Artiguenave, V C Blok, M-C Caillaud, P M Coutinho, C Dasilva, F De Luca, F Deau, M Esquibet, T Flutre, J V Goldstone, N Hamamouch, T Hewezi, O Jaillon, C Jubin, P Leonetti, M Magliano, T R Maier, G V Markov, P McVeigh, G Pesole, J Poulain, M Robinson-Rechavi, E Sallet, B Ségurens, D Steinbach, T Tytgat, E Ugarte, C van Ghelder, P Veronico, T J Baum, M Blaxter, T Blevé-Zacheo, E L Davis, J J Ewbank, B Favery, E Grenier, B Henrissat, J T Jones, V Laudet, A G Maule, H Quesneville, M-N Rosso, T Schiex, G Smant, J Weissenbach & P Wincker **1** see also p 882
- 916 A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types**
M Wernig, C J Lengner, J Hanna, M A Lodato, E Steine, R Foreman, J Staerk, S Markoulaki & R Jaenisch
- 925 Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index**
J R Junutula, H Raab, S Clark, S Bhakta, D D Leipold, S Weir, Y Chen, M Simpson, S P Tsai, M S Dennis, Y Lu, Y G Meng, C Ng, J Yang, C C Lee, E Duenas, J Gorrell, V Katta, A Kim, K McDorman, K Flagella, R Venook, S Ross, S D Spencer, W L Wong, H B Lowman, R Vandlen, M X Sliwkowski, R H Scheller, P Polakis & W Mallet **1** see also p 884
- 933 A small molecule enhances RNA interference and promotes microRNA processing**
G Shan, Y Li, J Zhang, W Li, K E Szulwach, R Duan, M A Faghihi, A M Khalil, L Lu, Z Paroo, A W S Chan, Z Shi, Q Liu, C Wahlestedt, C He & P Jin

LETTERS

- 941 Global identification of microRNA–target RNA pairs by parallel analysis of RNA ends**
M A German, M Pillay, D-H Jeong, A Hetawal, S Luo, P Janardhanan, V Kannan, L A Rymarquis, K Nobuta, R German, E De Paoli, C Lu, G Schroth, B C Meyers & P J Green **1** see also p 881

947 ERRATA

NATUREJOBS BIOTECHNOLOGY

CAREERS AND RECRUITMENT

- 949 Westernizing Eastern-bloc science**
Quirin Schiermeier

NATURE BIOTECHNOLOGY CLASSIFIED

See back pages.

952 PEOPLE